The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective obser...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2024-07, Vol.115 (7), p.2384-2395
Hauptverfasser:	Shimazu, Yutaka, Kanda, Junya, Suzuki, Kazuhito, Wada, Akinori, Kikuchi, Taku, Ikeda, Takashi, Tsukada, Nobuhiro, Miwa, Akiyoshi, Itagaki, Mitsuhiro, Kako, Shinichi, Nishiwaki, Kaichi, Ota, Shuichi, Fujiwara, Shin‐ichiro, Kataoka, Keisuke, Doki, Noriko, Sawa, Masashi, Hiramoto, Nobuhiro, Nishikawa, Akinori, Imai, Toshi, Ichinohe, Tatsuo, Kanda, Yoshinobu, Atsuta, Yoshiko, Kawamura, Koji
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Autografts autologous stem cell transplantation CD38 antigen Chi-square test Confidence intervals daratumumab Female Gender Hematopoietic Stem Cell Transplantation - methods Humans Male Medical prognosis Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality Multiple Myeloma - therapy Multivariate analysis Original ORIGINAL ARTICLE Prognosis Progression-Free Survival response Retrospective Studies Software packages Stem cell transplantation Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age
ISSN:	1347-9032 1349-7006 1349-7006
DOI:	10.1111/cas.16198